Search

Displaying results 6001 - 6010 of 10000 in total
  1. Drug

    Vintafolide

    go.drugbank.com/drugs/DB05168
    Investigational

    Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.

  2. Drug

    Bumetanide

    go.drugbank.com/drugs/DB00887
    ApprovedInvestigational

    Bumetanide is a sulfamyl diuretic.

  3. Drug

    NPS-2143

    go.drugbank.com/drugs/DB05695
    Experimental

  4. Drug

    Geneticin

    go.drugbank.com/drugs/DB04263
    Experimental

    Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea. … Geneticin blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells and is commonly used in laboratory research to select genetically engineered cells.

  5. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. … [A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.

    Synonyms: 4-N-Hydroxycytidine, N(4)-Hydroxycytidine
  6. Drug

    Deutarserine

    go.drugbank.com/drugs/DB19057
    Investigational

    Deutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).

  7. Drug

    Crisugabalin

    go.drugbank.com/drugs/DB19300
    Investigational

    Crisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to

  8. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  9. Drug

    Vercirnon

    go.drugbank.com/drugs/DB15250
    Investigational

    It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.

    International brands: Traficet-EN
  10. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.